Back

Jefferies sets $150 Nektar target, implying 219% upside

Verifying
  • Roger Song set a $150 price target for Nektar Therapeutics.
  • Nektar traded at $46.99, implying 219% upside to the target.
  • Nektar presented positive six-month Phase IIb results for alopecia drug REZPEG.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.